
    
      This study is a randomized, double-blind, multicenter, phase 2/3 study to evaluate the
      efficacy and safety of combined administration of TAK-536CCB and Hydrochlorothiazide (HCTZ)
      with those of TAK-536CCB or Hydrochlorothiazide in patients with grade I or II essential
      hypertension.

      This study consists of a 4-week single-blind placebo run-in period and a 10-week double-blind
      treatment period.
    
  